Reactive oxygen species (ROS) produced by tumor necrosis factor-a (TNF-a) have an important function in cell death by activating c-Jun N-terminal kinase. However, the exact mechanism of mitochondrial ROS production, after TNF-a stimulation, is not clearly understood. In this study, we determined that ROS modulator 1 (Romo1) and B-cell lymphoma-extra large (Bcl-X L ) are directly associated with TNF-a-induced ROS production. In response to TNF-a, TNF complex II, which consists of receptorinteracting protein 1, TNF receptor-associated protein with death domain, TNF receptor-associated factor 2, Fas-associated death domain protein, and pro-caspase-8, binds to the C-terminus of Romo1 located in the mitochondria. Concurrently, Romo1 recruits Bcl-X L to reduce the mitochondrial membrane potential, resulting in ROS production and apoptotic cell death. On the basis of these results, we suggest that Romo1 is a molecular bridge between TNF-a signaling and the mitochondria for ROS production that triggers TNF-a-mediated apoptosis, as well as a novel target in the development of anti-inflammatory agents that block the origin of ROS production. Tumor necrosis factor-a (TNF-a) is a major mediator of inflammation. There are two main pathways in TNF-a signaling. One is the pro-survival/pro-inflammatory pathway that activates NF-kB and MAPK through TNF-a-induced signaling complex I.
Tumor necrosis factor-a (TNF-a) is a major mediator of inflammation. There are two main pathways in TNF-a signaling. One is the pro-survival/pro-inflammatory pathway that activates NF-kB and MAPK through TNF-a-induced signaling complex I. 1 After binding of the trimeric TNF-a to the cell surface receptor TNF-R1, the silencer of death domain dissociates from TNF-R1 complexes, and the TNF receptor-associated protein with death domain (TRADD) -an adaptor protein -binds to the cytoplasmic domain of the receptor. 2 TRADD recruits additional proteins including TNF receptor-associated factor 2 (TRAF2), receptor-interacting protein 1 (RIP1), and cellular inhibitor of apoptosis proteins to form TNF-a-induced signaling complex I. 3, 4 The other TNF-a signaling pathway is the proapoptotic pathway through TNF-ainduced signaling complex II, in which reactive oxygen species (ROS), a caspase cascade, and the mitochondria function as downstream mediators. If TRADD, TRAF2, and RIP1 dissociate from the receptor, they recruit Fas-associated death domain protein (FADD) and pro-caspase-8 to form TNF-a-induced signaling complex II, which is implicated in signaling apoptosis. 5, 6 This TNF-a-induced cell death pathway is normally blocked by concomitant activation of NF-kB.
ROS generation, after TNF-a binding, has been reported to be involved in both cell survival and cell death, and the main source of ROS generation that contributes to TNF-a-induced cell death is the mitochondrion. [7] [8] [9] However, another study reported that NADPH oxidase is the source of ROS generation after TNF-a treatment. 10 ROS are known to contribute to cell death by inducing mitochondrial membrane permeabilization and sustaining c-Jun N-terminal kinase (JNK) activation. 11, 12 JNK is activated by the activation of apoptosis signal-regulating kinase-1 or by ROS-mediated inactivation of MKPs. 13, 14 There are several reports regarding the mechanism of JNK-induced apoptosis in response to TNF-a. JNK induces cFLIP degradation through Itch activation to trigger apoptosis. [15] [16] [17] JNK also contributes to TNF-a-stimulated cell death by cleavage of Bid into jBid, which stimulates the release of Smac/Diablo into the cytosol to activate caspases. 18 B-cell lymphoma-extra large (Bcl-X L ) is known to stabilize Dcm to maintain mitochondrial homeostasis. 19, 20 Bcl-X Lpromoted Dcm stabilization seems to prevent cell death because massive cell death was observed in Bcl-X L -deficient mice. 21 TNF-a/D-GalN-induced cell death from a variety of stimuli was blocked by Bcl-X L overexpression. 22 , 23 Gottlieb et al. 24 suggested that TNF-a treatment induces an early decrease in Dcm and subsequent ROS formation, which promotes a late decrease in Dcm, and that Bcl-X L expression inhibits the early decrease in Dcm and the subsequent ROS generation after TNF-a stimulation.
ROS modulator 1 (Romo1) is localized in the mitochondria and induces mitochondrial ROS production through complex III of the mitochondrial electron transport chain. [25] [26] [27] The ROS originating from the endogenous Romo1 protein appear to be indispensable for both normal and cancer cell proliferation, because Romo1 knockdown inhibits cell-cycle transition through inhibition of Erk activation and p27
Kip1 expression. 28, 29 Romo1 expression is induced by an external stimulus such as 5-FU, and it is upregulated in senescent cells and in most cancer cells. 25, 26, 30 As the mitochondrial origin of ROS formation triggered by TNF-a is not clear, and Romo1 contributes to ROS production in the mitochondria, we investigated whether TNF-a-induced ROS are associated with Romo1.
Results
Romo1 is responsible for TNF-a-induced ROS production. We examined TNF-a-induced ROS production by staining cells with the oxidant-sensitive dye, 5-(and-6)-chloromethyl-2 0 ,7 0 -dichlorodihydrofluorescein diacetate acetyl ester (CM-H 2 DCFDA), after Romo1 knockdown by Romo1 small-interfering RNA (siRNA) transfection. As ROS produced by TNF-a are eliminated by FHC and MnSOD, which are products of TNF-a-activated NF-kB signaling, 31 cells were treated with the translation inhibitor, cycloheximide (CHX), to suppress NF-kB signaling stimulated by TNF-a. As expected, TNF-a treatment increased ROS levels in cells pretreated with CHX ( Figure 1a) . Interestingly, the TNF-astimulated ROS increase was completely blocked by Romo1 knockdown. The decrease in ROS formation was quantified using MetaMorph software and is illustrated in HeLa cells ( Figure 1a ) and human embryo kidney (HEK) 293 cells (Supplementary Figure S1a) . Butylated hydroxy anisol (BHA), an antioxidant, was also added to cells pretreated with CHX. The ROS level in these cells was downregulated by Romo1 knockdown itself (Figure 1 ), which is consistent with earlier reports. 28, 29 This experiment was also carried out again in the cells treated with H 2 O 2 as a positive control. HeLa cells were transfected with 100 nM of control siRNA or Romo1 siRNA for 16 h and treated with H 2 O 2 (100 mM) for 1 h. As expected, ROS increase was observed in the cells transfected with control siRNA (Supplementary Figure S1b) . Interestingly, ROS production induced by H 2 O 2 treatment was blocked in the cells transfected with Romo1 siRNA. It has been reported that ROS induces ROS release. 32 Therefore, we suggest that H 2 O 2 treatment induces ROS production through Romo1. The exact mechanism as to how Romo1 may be involved in H 2 O 2 -triggered ROS induction is now under investigation. Suppression of a TNF-a-induced ROS increase by Romo1 knockdown was also observed by flow cytometry, and the same result was obtained in HeLa cells (Figure 1b) and HEK 293 cells (Supplementary Figure  S1c) . As dominant negative-I-kB (DN-I-kB) overexpression inhibits NF-kB translocation to the nucleus, DN-I-kB was transfected into HeLa cells to inhibit the TNF-a-induced NF-kB activation. Blockage of TNF-a-stimulated nuclear translocation of NF-kB on DN-I-kB expression was observed by immunofluorescence analysis (Figure 1c ). TNF-a treatment also increased ROS levels in cells transfected with DN-I-kB, and the ROS increase was completely suppressed by Romo1 knockdown in HeLa cells ( Figure 1d ) and HEK 293 cells (Supplementary Figure S1d) . The inhibition of ROS formation was quantified by MetaMorph software and is shown in Figure 1e and Supplementary Figure 1e . Suppression of TNF-a-induced ROS formation by Romo1 knockdown was also observed by flow cytometry (Figure 1f ). To measure the transfection efficiency of Romo1 siRNA by flow cytometry, Romo1 siRNA-FITC was transfected into these two cell lines; the Romo1 siRNA transfection efficiencies were above 90% (data not shown). Romo1 knockdown was examined by western blotting (Figure 1g ) or RT-PCR (Supplementary Figure  S1f) , and the result was consistent with earlier reports. [26] [27] [28] [29] TNF-a-induced JNK activation and cell death are regulated by Romo1-mediated ROS production. We examined whether Romo1 regulated TNF-a-triggered JNK activation and cell death. As shown in Figure 2a , TNF-a treatment induced prolonged JNK activation in cells pretreated with CHX, and Romo1 knockdown inhibited this JNK activation. Next, we examined whether Romo1 was involved in TNF-a-induced apoptotic cell death. Romo1 siRNA was transfected into HeLa cells, and cell death was observed after TNF-a treatment. Figure 2b and Supplementary Figure S2a show that TNF-a stimulation in the presence of CHX induced cell death, and that cell death was inhibited by Romo1 knockdown or BHA treatment. However, Romo1 siRNA transfection failed to completely inhibit cell death, showing that another signaling pathway independent of Romo1 also exists in TNF-a-stimulated cell death. To observe apoptotic body formation in TNF-ainduced cell death, we stained cells with DAPI and visualized them by fluorescence microscopy after Romo1 knockdown. As shown in Figure 2c and Supplementary Figure S2b , TNF-a treatment increased the formation of apoptotic bodies, whereas Romo1 knockdown decreased their formation. To see the cleavage of mediators involved in TNF-a-induced apoptosis, western blotting was performed after Romo1 knockdown. Figure 2d shows that cleavage of caspase-8, caspase-3, PARP, RIP1, and Bid was observed after TNF-a treatment, and that Romo1 knockdown inhibited these cleavages, showing that Romo1 is an upstream mediator of caspase-8 and Bid in TNF-a-triggered apoptosis. Next, cells were treated with zVAD, a caspase inhibitor, before TNF-a treatment to determine whether zVAD blocked TNF-a-induced cell death. As expected, Romo1 knockdown partially inhibited TNF-a-induced cell death, whereas zVAD treatment more effectively prevented cell death (Figure 2e; Supplementary Figure S2c) . These results show that Romo1 is an important mediator of cell death triggered by TNF-a.
TNF-a-induced signaling complex II binds to the C-terminal region of Romo1 in response to TNF-a. To see the interaction between endogenous Romo1 and TNF complex II, RIP1 was immunoprecipitated with anti-RIP1 antibody, and western blotting was performed with an antiRomo1 antibody. Figure 3a shows that RIP1 interacted with endogenous Romo1 at 15 min and continued to 4 h during TNF-a stimulation. To confirm this interaction, Flag-tagged Romo1 was transfected into HEK 293 cells, and the Romo1 protein was immunoprecipitated with Flag antibody to perform western blotting with RIP1, TRADD, TRAF-2, In an earlier report, we suggested that Romo1 is a transmembrane protein with a molecular weight of approximately 8.9 kDa. 25 The transmembrane domain was also predicted using SMART (http://smart.embl-heidelberg.de) and CBS Prediction Servers (http://www.cbs.dtu.dk/services/ TMHMM). Therefore, we made two deletion mutants of Romo1, designated Romo1-DC and Romo1-DN, and Figure 3f , the C-terminal region of Romo1 interacted with TNF-a-induced signaling complex II, showing that the C-terminal domain of Romo1 was oriented into the cytosol. Next, we observed whether these deletion mutants localized to the mitochondria and induced mitochondrial ROS generation. Figure 3g and h shows that only the N-terminal deletion mutant localized to the mitochondria and enhanced ROS levels. In contrast, the C-terminal deletion mutant was found in the whole cell and failed to generate mitochondrial ROS. These results show that the mitochondrial localization signal is located in the C-terminal domain and that the C-terminal domain is important for TNF-ainduced ROS production. To test the Romo1 topology, the mitochondria were isolated from HEK 293 cells transfected with N-terminally Flag-tagged Romo1 or C-terminally myctagged Romo1. After digestion with proteinase K in the presence or absence of Triton X-100, western blotting was performed using anti-Flag or myc antibodies. As shown in Figure 4 , the C-terminally myc-tagged Romo1 was digested by proteinase K. However, the N-terminally Flag-tagged Romo1 protein remained. Instead, the N-terminally Flagtagged Romo1 was detected at a smaller size. This result shows that the C-terminus of Romo1 is exposed to the cytosol. Voltage-dependent anion channel (VDAC), in the outer mitochondrial membrane, and Mn-SOD, in the mitochondrial matrix, were used as positive controls.
TNF-a-induced initial decrease of Dwm through Romo1 is followed by ROS production. TNF-a induces the initial decrease of Dcm, leading to ROS generation and subsequent loss of Dcm, which triggers ROS formation to induce apoptosis. 24, 33 To (Figure 5a and b) . After TNF-a treatment, the decrease of Dcm was detected by fluorescence microscopy in cells transfected with control siRNA; this decrease of Dcm was inhibited by Romo1 knockdown or BHA treatment (Figure 5a and b) . Interestingly, although the TNF-a-induced decrease in Dcm was inhibited by Romo1 knockdown at 15 min, the TNF-ainduced decrease of Dcm was not blocked by BHA treatment (Figure 5a and b) . The earlier report showed that Romo1-mediated ROS production was generated from the mitochondrial electron transport chain. 26 Therefore, we examined whether the inhibitors of the mitochondrial electron transport chain blocked the initial decrease of Dcm after TNF-a stimulation. Stigmatellin or rotenone also failed to inhibit the initial TNF-a-induced decrease of Dcm (Figure 5a and b). These results indicate that the initial TNF-a-induced decrease of Dcm (at 15 min) was only blocked by Romo1 knockdown, and that the initial decrease of Dcm mediated by Romo1 after TNF-a stimulation was independent of ROS production. As shown in Figure 5b , the decrease of Dcmindicated by the downshift of the dotted squares -was accelerated in control cells at 4 h, and BHA or stigmatellin treatment inhibited the late TNF-a-induced decrease of Dcm (at 4 h). Figure 5f ). The change of Dcm was quantified using MetaMorph software and is illustrated in Figure 5g . On the basis of these results, we suggest that Romo1 mediates the early TNF-a-induced decrease of Dcm to trigger ROS production, which leads to the late decrease of Dcm and subsequent ROS accumulation.
Romo1 regulates TNF-a-induced early decrease of Dwm through interaction with Bcl-X L . First, we examined whether endogenous Romo1 interacted with the Bcl-X L protein through coimmunoprecipitation assays. To examine this interaction, Bcl-X L was immunoprecipitated with its antibody, and western blotting was performed with antiRomo1 antibody. As shown in Figure 6a , Bcl-X L was associated with Romo1, but not with TNF-a-induced signaling complex II components. Interestingly, Bax was released from Bcl-X L after TNF-a stimulation, and Romo1 showed weak binding with Bcl-X L without TNF-a stimulation (Figure 6a Figure 6b ). Using deletion mutants of Romo1, we explored which region of Romo1 was required for binding to Bcl-X L . As shown in Figure 6c , the C-terminal region of Romo1 was necessary for binding to Bcl-X L .
In this study, we showed an early TNF-a-induced decrease of Dcm through Romo1 and the interaction of Romo1 with Bcl-X L . Therefore, we examined whether the early TNF-ainduced decrease of Dcm mediated by Romo1 was regulated by Bcl-X L . As shown in Figure 7a , the downshift of dots was increased in cells transfected with Romo1 and inhibited by Bcl-X L expression. Figure 7b shows the quantified data of Figure 7a by representing the ratio of the signal of high Dcm (red) to the signal of low Dcm (green). Next, we examined whether Bcl-X L prevented the early TNF-a-induced decrease of Dcm (at 15 min). As shown in Figure 7c -e, the early TNF-ainduced decrease of Dcm was blocked by Bcl-X L expression. From these results, we suggest that Romo1 mediated the early TNF-a-induced decrease of Dcm by binding to Bcl-X L and preventing its function.
Bcl-X L prevents TNF-a-induced cell death mediated by Romo1. TNF-a-induced cell death is known to be suppressed by Bcl-X L expression. 24 We also investigated whether Bcl-X L prevented TNF-a-induced ROS production; this production was measured by flow cytometry after Bcl-X L transfection. As shown in Figure 8a overexpression blocked TNF-a-induced ROS formation. Next, we investigated whether Bcl-X L prevented Romo1-induced cell death. After Bcl-X L and Romo1 were transfected into HeLa cells, the number of cells was counted. As shown in Figure 8c , Bcl-X L prevented Romo1-induced cell death. To address whether TNF-a-induced cell death mediated by Romo1 was regulated by Bcl-X L , HeLa cells were transfected with Romo1, Bcl-X L , or Romo1 and Bcl-X L . As shown in Figure 8d , Bcl-X L effectively inhibited not only TNF-a-induced cell death, but also TNF-a-induced cell death enhanced by Romo1 expression. In Figure 6c , we showed that the C-terminal region of Romo1 was important for binding to Bcl-X L . Therefore, HeLa cells were transfected with the C-terminal region of Romo1 or the N-terminal region of Romo1. The C-terminal region of Romo1, as well as the full-length version, did induce cell death (Figure 8e ; Supplementary Figure S4) . Unexpectedly, the N-terminal region of Romo1 also induced cell death. We do not know why the N-terminal region of Romo1 also induced cell death, and this requires further investigation. However, Bcl-X L expression effectively recovered the cell death enhanced by the C-terminal region of Romo1, but not the cell death enhanced by the N-terminal region of Romo1.
Discussion
ROS have an important function in cell survival and cell death triggered by TNF-a signaling, and the main source in ROS generation required for TNF-a-induced cell death is the mitochondria. 8,34-36 Therefore, we were curious whether Romo1 was involved in TNF-a-induced ROS production, because Romo1 is located in the mitochondrial membrane and induces ROS generation. 25 As shown in Figure 1 , TNF-atriggered ROS production was completely blocked by Romo1 knockdown, and the same result was obtained with BHA treatment. This result shows that Romo1 is responsible for TNF-a-induced ROS production, and that Romo1 should be located in the outer membrane of the mitochondria to sense the signal elicited by TNF-a. In our earlier report, we showed that the molecular weight of Romo1 is approximately 8.9 kDa, and that Romo1 is a transmembrane protein with a single transmembrane domain. 25 In this study, we showed that Romo1 is associated with TNF complex II, which consists of RIP1, TRADD, TRAF2, FADD, and pro-caspase-8, in response to TNF-a stimulation, and that the C-terminus of Romo1 interacts with TNF-a-induced signaling complex II (Figure 3) . From the results obtained in this study, we suggest that TNF-a-induced signaling complex II interacts with the C-terminus of Romo1, which is oriented into the cytosol, and transmits the TNF-a signal to mitochondria. It is unlikely that Romo1 generates ROS in response to TNF-a signaling similar to NADPH oxidase and other enzymes such as xanthine oxidase, cyclooxygenases, and lipoxygenases. Romo1 consists of 79 amino acids and has no homology domain when compared with these enzymes. It seems that Romo1, which is located in the mitochondrial outer membrane, functions as a modulator to supply ROS from complex III of the mitochondrial respiratory chain into the cytosol when the TNF-a signal is delivered to mitochondria through TNF-a-induced signaling complex II.
How does Romo1 modulate ROS release from mitochondria? Our suggestion is that Romo1 transmits the TNFa-triggered signal to mitochondria by forming a complex with Bcl-X L to decrease Dcm, resulting in ROS production. Bcl-X L has been reported to stabilize mitochondrial membrane potential (Dcm) to maintain mitochondrial homeostasis. 19, 20 An early event in Romo1-mediated ROS production is the concurrent binding of the C-terminus of Romo1 to Bcl-X L , compared with Romo1 binding to TNF-a-induced signaling complex II (Figure 6 ). Interestingly, Bcl-X L binding to TNF-ainduced signaling complex II is not observed in response to TNF-a. This result indicates that TNF-a-induced signaling complex II-Romo1 binding and Romo1-Bcl-X L interaction occurred simultaneously, and that TNF-a-induced signaling complex II-Romo1 binding led to Romo1-Bcl-X L interaction. We do not know the exact mechanism by which TNF-ainduced signaling complex II-Romo1 induces Romo1-Bcl-X L interaction, and this remains to be clarified through further study. The second event is the loss of Dcm resulting from Romo1-Bcl-X L interaction, which triggers ROS formation. In this study, the TNF-a-induced decrease of early Dcm was inhibited by Romo1 knockdown; however, it was not blocked by BHA or mitochondrial complex inhibitors ( Figure 5) , showing that the initial TNF-a-induced decrease of Dcm is an early event before ROS induction. Our results also showed that Bcl-X L overexpression suppressed these events, which were triggered by TNF-a stimulation (Figure 7) . Thus, Romo1 interacts with Bcl-X L to decrease Dcm, leading to subsequent ROS generation after TNF-a stimulation. Interestingly, a basal level of interaction between Romo1 and Bcl-X L was observed without TNF-a treatment ( Figure 6 ). Romo1 overexpression without TNF-a treatment, therefore, induces the loss of Dcm and enhances ROS levels. We showed that Romo1 overexpression caused the loss of Dcm in this study (Figure 7b ), whereas ROS levels increased by Romo1 overexpression in an earlier report. 25 These findings show that the basal interaction between Romo1 and Bcl-xL is important for ROS supply into the cytosol even without stimuli. Consistent with this suggestion, we showed that Romo1 knockdown decreased ROS levels in both normal and tumor cells. 28, 29 Taken together, Romo1 is an important modulator to supply ROS into the cytosol. Without any signal, Romo1 supplies the minimal level of ROS required for cell survival and proliferation through the basal binding of Romo1 to Bcl-X L . If the cell needs enhanced ROS levels in response to a signal such as TNF-a, Romo1 recruits more Bcl-X L to increase ROS levels. The proposed TNF-a-induced ROS signaling pathway mediated by Romo1 is shown in Figure 9 .
Cell life or death, after TNF-a stimulation, is well controlled by the crosstalk between the pro-survival pathway and the proapoptotic pathway. Upregulated production of TNF-a or inappropriate activation of TNF-a signaling has been reported to contribute to a variety of diseases.
3 TNF-a-induced cell death can be initiated by the mitochondria-dependent pathway (intrinsic pathway) or by the mitochondria-independent pathway (extrinsic pathway). 37 In this study, we showed that Romo1 mediated TNF-a-induced ROS generation by forming a complex with TNF-a-induced signaling complex II and with Bcl-X L . However, Romo1 knockdown with Romo1 siRNA could not completely inhibit TNF-a-induced apoptotic cell (Figure 2 ). In the extrinsic pathway, death receptor recruits pro-caspase-8 in TNF-a-induced signaling complex II and activates the caspase cascade to induce apoptotic cell death. Therefore, we assume that TNF-a-induced cell death in the presence of CHX can occur through both pathways, and that Romo1 knockdown inhibits only the mitochondriadependent cell death pathway.
Materials and Methods
Cell culture and reagents. HEK 293 cells and HeLa cervix carcinoma cells were cultured in Dulbecco's modified Eagle's media (Gibco-Invitrogen, Grand Island, NY, USA) supplemented with 10% heat-inactivated FBS (Gibco-Invitrogen), sodium bicarbonate (2 mg/ml; Sigma-Aldrich, St. Louis, MO, USA), penicillin (100 units/ml), and streptomycin (100 mg/ml; Gibco-Invitrogen) and grown in 5% CO 2 at 371C. Human recombinant TNF-a was obtained from R&D System. zVAD, BHA, stigmatellin, rotenone, and TMRM were purchased from Sigma-Aldrich. CM-H 2 DCFDA, MitoSOX, and JC-1 were obtained from Molecular Probes (Eugene, OR, USA). siRNA transfections. Bioneer (Taejon, Republic of Korea) synthesized double-stranded siRNA oligonucleotides targeting Romo1. 30 The cells (1 Â 10 5 ) were seeded into six-well plates and then transfected with Romo1 siRNA using Lipofectamine (Gibco-Invitrogen) in cells at 70% confluency according to the manufacturer's instructions.
Plasmids. PCR amplification was performed to generate the Romo1 mutants using the following primers containing the BamHI or EcoRI restriction enzyme site: forward, 5 0 -GATCGGATCCCGCCGCCACCATGCCGGTGGCCGTG -3 0 and reverse, 5 0 -GATCGAATTCCTTTACATTCCGATCCTGAGACAGGAAAAG-3 0 for Romo1-DC; forward, 5 0 -GATCGGATCCCGCCGCCACCATGGACCGTGTCAAAA TG-3 0 and reverse, 5 0 -GATCGAATTCCTTTAGCATCGGATGCCCATCCC-3 0 for Romo1-DN. The PCR products were cloned into pFlag-C1 vector. Dr. Xiao-Ming Yin (Beckman Research Institute, Duarte, CA, USA) kindly provided the Bcl-XL plasmid.
ROS assay. Intracellular ROS levels were measured by a fluorescence microscope (Olympus LX71 microscope; Olympus, Tokyo, Japan) or a FACScan flow cytometer (Becton Dickson, San Jose, CA, USA) using CM-H 2 DCFDA (50 mM) or MitoSOX (5 mM), as described earlier. 26 Measurement of Dwm. To determine changes in Dcm, HeLa cells treated with TNF-a (20 ng/ml) with or without CHX (10 mg/ml) were incubated with JC-1 (5 mM) for 30 min or TMRM (100 nM) for 15 min at 371C. JC-1 was excited at 490 nm. Emission fluorescence was filtered and images were collected for FITC (green, 530 nm) and TRITC (red, 590 nm) channels using the FACScan flow cytometer (Becton Dickson). TMRM-stained cells were examined, using a fluorescence microscope (Olympus LX71 microscope), for excitation at 510-560 nm and with an emission filter for 570-620 nm. For quantification purposes, TMRM fluorescence was analyzed with MetaMorph software (Universal Imaging, Westchester, PA, USA).
Immunoprecipitation. HEK 293 cells were plated onto 100-mm dishes and transfected with Flag-tagged Romo1. Cell lysates prepared in IP lysis buffer [50 mM Tris-HCl (pH 7.5), 120 mM NaCl, 0.5% NP-40, 50 mM NaF, 200 mM Na3VO4, 1 mM PMSF, 1 mM EDTA, 10% Glycerol] were incubated with anti-FLAG antibody (M2) or indicated antibodies. After the addition of protein G-agarose beads, cell lysates were incubated at 41C overnight. After washing with IP lysis buffer, the immunoprecipitants were subjected to western blotting using the indicated antibodies.
Analysis of topology. Intact mitochondria were isolated from HEK 293 cells, transfected with Flag-Romo1 or Romo1-myc using an ApoAlert cell fractionation kit (Clontech, Mountain View, CA, USA), and analysis of topology was carried out as described earlier. 38 Statistical analysis. Each assay was performed in triplicate and independently repeated at least three times. Statistical significance was defined as Po0.05. Means, S.E.s, and Ps were calculated using GraphPad PRISM version 4.02 for Windows (GraphPad Software, San Diego, CA, USA).
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